Daniel E. Geffken - 14 Feb 2024 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Role
Chief Financial Officer
Signature
/s/ Chris Ehrlich, Attorney-in-Fact
Issuer symbol
CERO
Transactions as of
14 Feb 2024
Transactions value $
$0
Form type
4
Filing time
16 Feb 2024, 19:39:38 UTC
Previous filing
30 Oct 2023
Next filing
20 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERO Class A Common Stock Other +10K 10K 14 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel E. Geffken is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration.